Nutzen und Grenzen von Studien mit Surrogat-Endpunkten in der klinischen Entscheidungsfindung
- 1 January 2010
- journal article
- research article
- Published by Elsevier in Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
- Vol. 104 (3) , 230-237
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialThe Lancet, 2007
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Fluoride for the Treatment of Postmenopausal Osteoporotic Fractures: A Meta-AnalysisOsteoporosis International, 2000
- Users' Guides to the Medical LiteratureJAMA, 1999
- A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)American Heart Journal, 1997
- Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart FailureJAMA, 1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or PlaceboNew England Journal of Medicine, 1991
- A Comparison of Oral Milrinone, Digoxin, and Their Combination in the Treatment of Patients with Chronic Heart FailureNew England Journal of Medicine, 1989
- Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial.Circulation, 1989